Tanja Schimek-Jasch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8152013/publications.pdf

Version: 2024-02-01

759233 794594 19 483 12 19 citations h-index g-index papers 19 19 19 830 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 581-592.	10.7	121
2	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) $\hat{a} \in \text{``protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer, 2016, 16, 769.}$	2.6	62
3	Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics. PLoS ONE, 2019, 14, e0217536.	2.5	38
4	Impact of 4D-18FDG-PET/CT imaging on target volume delineation in SBRT patients with central versus peripheral lung tumors. Multi-reader comparative study. Radiotherapy and Oncology, 2015, 115, 335-341.	0.6	37
5	A teaching intervention in a contouring dummy runÂimproved target volume delineation in locally advanced non-small cell lung cancer. Strahlentherapie Und Onkologie, 2015, 191, 525-533.	2.0	31
6	User Interaction in Semi-Automatic Segmentation of Organs at Risk: a Case Study in Radiotherapy. Journal of Digital Imaging, 2016, 29, 264-277.	2.9	28
7	FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?. Radiation Oncology, 2021, 16, 46.	2.7	24
8	FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy. Cancers, 2021, 13, 814.	3.7	21
9	Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Radiotherapy and Oncology, 2020, 148, 82-88.	0.6	20
10	Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization. Translational Lung Cancer Research, 2017, 6, 670-688.	2.8	18
11	Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial). Journal of Thoracic Oncology, 2019, 14, 408-419.	1.1	15
12	Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 565-580.	2.4	14
13	Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1161.	2.8	14
14	Using a contextualized sensemaking model for interaction design: A case study of tumor contouring. Journal of Biomedical Informatics, 2017, 65, 145-158.	4.3	12
15	Visualization of 4D multimodal imaging data and its applications in radiotherapy planning. Journal of Applied Clinical Medical Physics, 2017, 18, 183-193.	1.9	10
16	Less is more? Imaging-based target volume reduction – Authors' reply. Lancet Oncology, The, 2020, 21, e303.	10.7	6
17	Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial. Radiotherapy and Oncology, 2021, 163, 32-38.	0.6	6
18	Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. Cancers, 2021, 13, 5725.	3.7	5

#	Article	IF	CITATIONS
19	Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer: Simultaneus intergrated protection (SIP) versus conventional SBRT A toxicity review of two different treatment approaches Journal of Clinical Oncology, 2016, 34, e15692-e15692.	1.6	1